The article analyzes a nutraceutical combination based on Tanacetum Parthenium (partenio titled in Parthenolide), Griffonia simplicifolia and magnesium, (AuraSTOP), in the acute phase of migraine aura.

Migraine with aura is a particular form of migraine, characterized by the appearance of transient, visual, sensitive or language neurological symptoms that precede or accompany the painful phase.

The aura is related to a neurophysiological phenomenon known as Cortical Spreading Depression (CSD), a temporary alteration of brain electrical activity1.

A retrospective cohort study was carried out involving subjects with migraines with aura who took AuraSTOP at the onset of aurasic symptoms. The main objective was to evaluate the reduction in the duration of the aura and the possible attenuation of the subsequent painful phase. The results obtained were compared with those relating to previous attacks treated with other or untreated strategies.

From a rational point of view, the three components of the formulation have potentially useful properties in modulating the pathophysiological mechanisms of the aura: the Partenio has anti-inflammatory activity and modulates the release of neurotransmitters;2 Griffonia simplicifolia is a natural source of 5-hydroxytryptophan (5-HTP), a precursor of serotonin, implicated in the mechanisms of migraine;3 Magnesium contributes to the stabilization of neuronal membranes and can counteract cortical hyperexcitability associated with CSD.4

The results of the study show that the early intake of AuraSTOP is associated with a significant reduction in the duration of the aura compared to previous episodes and, in many cases, a reduction in intensity or the lack of subsequent headache. The product was generally well tolerated, with the absence of significant undesirable effects reported in the analyzed cohort.

Pretrattamento (t1) Post-trattamento (t2) P
Duration of the aura, minutes 33,6 ± 10,1 9,4 ± 6,2 <0,01*
Type of aura, code 1[1 – 1] 1[1 – 2] <0,05§
Disability, Score 5[4 – 5] 1[1-2] <0,01§
Headache attacks, number 3[3] – 3] 2[2] – 3] <0,01§
Duration of the headache, minutes 24,9 ± 7,4 5,1 ± 5,0 <0,01*
Headache intensity, NRS-11 score 8[7 – 9] 3[2 – 4] <0,01§
Use of rescue medications, number 3[3] – 3] 1[1 – 3] <0,01§
Response to symptomatic treatment, score 2[1 – 2] 4[4 – 5] <0,01§

The authors conclude that the combination of Tanacetum Parthenium, Griffonia simplicifolia and Magnesium can represent a safe and potentially effective support option in the acute clinical setting of the migraine aura, especially if taken early. However, since it is a retrospective and non-randomized study, they underline the need for further prospective, controlled and larger samples to confirm these results and better clarify the mechanism of action of the combination.

In summary, the study suggests that a nutraceutical approach aimed at the neurobiological mechanisms of the aura could offer an interesting alternative or integration to traditional pharmacological therapies.

  1. Costa C., et al. Cortical spreading depression as a target for anti-migraine agents. The Journal of Headache and Pain. 2013;4-62
  2. Wider B., et al. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;4(4):CD002286.
  3. Aggarwal M., et al. Serotonin and CGRP in migraine. Ann Neurosci. 2012;19(2):88-94.
  4. Sun-Edelstein C., et al. Role of magnesium in the pathogenesis and treatment of migraine. Expert Rev Neurother. 2009;9(3):369-79.

Related articles